APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid-ß. | JAMA Neurol;80(12): 1269-1271, 2023 Dec 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

APOE Genotype in the Era of Disease-Modifying Treatment With Monoclonal Antibodies Against Amyloid-ß.

Ossenkoppele, Rik; van der Flier, Wiesje M.

Affiliation

Ossenkoppele R; Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam University Medical Center, Amsterdam, the Netherlands.
van der Flier WM; Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands.

JAMA Neurol ; 80(12): 1269-1271, 2023 Dec 01.

Article in En | MEDLINE | ID: mdl-37930662

Subject(s)

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Antibodies, Monoclonal Limits: Humans Language: En Journal: JAMA Neurol Year: 2023 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Alzheimer Disease / Antibodies, Monoclonal Limits: Humans Language: En Journal: JAMA Neurol Year: 2023 Document type: Article Affiliation country: Países Bajos Country of publication: Estados Unidos